Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781081 | 0.95 | TDP1 (0.68) | TDP1MAPTRXFP1FAAHCES1 | |
| SCHEMBL1788500 | 0.95 | TDP1 (0.68) | TDP1MAPTRXFP1FAAHCES1 | |
| SCHEMBL28574865 | 0.91 | MAPT (0.72) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL1681599 | 0.91 | MAPT (0.72) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL1788501 | 0.91 | MAPT (0.72) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL28587263 | 0.91 | MAPT (0.72) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL19643833 | 0.90 | TDP1 (0.70) | TDP1MAPTRXFP1FFAR1LMNA | |
| SCHEMBL7284783 | 0.89 | TDP1 (0.60) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL8868323 | 0.89 | TDP1 (0.60) | TDP1MAPTRXFP1FFAR1LPAR1 | |
| SCHEMBL7292076 | 0.89 | TDP1 (0.60) | TDP1MAPTRXFP1FFAR1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128608-A1 | Novel chemical compounds and their use | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2006-06-15 | — | — | US | disclosed |
| WO-2004050677-A1 | NOVEL CHEMICAL COMPUNDS AND THEIR USE | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128608-A1 | Novel chemical compounds and their use | PGLS, ABCG2, UGCG | TDP1 3631/4885MAPT 3254/4885RXFP1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.